Manlangit, Baby Boy .
HRN: 26-44-82 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/11/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
01/11/2025
01/18/2025
IV
300mg
Q12
UTI, PSNB
Waiting Final Action
Indication: Empiric Type of Infection: Urinary TractPneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes